mRNA-1273 对抗 COVID-19 在 Delta 时期的持久性：一项观察性队列研究的中期结果。
Durability of mRNA-1273 against COVID-19 in the time of Delta: Interim results from an observational cohort study.
机构信息
Department of Research and Evaluation, Kaiser Permanente Southern California, Pasadena, CA, United States of America.
Department of Epidemiology, University of Alabama at Birmingham, Birmingham, AL, United States of America.
出版信息
PLoS One. 2022 Apr 28;17(4):e0267824. doi: 10.1371/journal.pone.0267824. eCollection 2022.
BACKGROUND
We conducted a prospective cohort study at Kaiser Permanente Southern California to study the vaccine effectiveness (VE) of mRNA-1273 over time and during the emergence of the Delta variant.
METHODS
The cohort for this planned interim analysis consisted of individuals aged ≥18 years receiving 2 doses of mRNA-1273 through June 2021, matched 1:1 to randomly selected unvaccinated individuals by age, sex, and race/ethnicity, with follow-up through September 2021. Outcomes were SARS-CoV-2 infection, and COVID-19 hospitalization and hospital death. Cox proportional hazards models were used to estimate adjusted hazard ratios (aHR) with 95% confidence intervals (CIs) comparing outcomes in the vaccinated and unvaccinated groups. Adjusted VE (%) was calculated as (1-aHR)x100. HRs and VEs were also estimated for SARS-CoV-2 infection by age, sex, race/ethnicity, and during the Delta period (June-September 2021). VE against SARS-CoV-2 infection and COVID-19 hospitalization was estimated at 0-<2, 2-<4, 4-<6, and 6-<8 months post-vaccination.
RESULTS
927,004 recipients of 2 doses of mRNA-1273 were matched to 927,004 unvaccinated individuals. VE (95% CI) was 82.8% (82.2-83.3%) against SARS-CoV-2 infection, 96.1% (95.5-96.6%) against COVID-19 hospitalization, and 97.2% (94.8-98.4%) against COVID-19 hospital death. VE against SARS-CoV-2 infection was similar by age, sex, and race/ethnicity, and was 86.5% (84.8-88.0%) during the Delta period. VE against SARS-CoV-2 infection decreased from 88.0% at 0-<2 months to 75.5% at 6-<8 months.
CONCLUSIONS
These interim results provide continued evidence for protection of 2 doses of mRNA-1273 against SARS-CoV-2 infection over 8 months post-vaccination and during the Delta period, and against COVID-19 hospitalization and hospital death.
背景
我们在 Kaiser Permanente Southern California 进行了一项前瞻性队列研究，以研究 mRNA-1273 的疫苗有效性（VE）随时间的变化以及在 Delta 变异出现时的变化。
方法
本计划的中期分析队列包括 2021 年 6 月前接受 2 剂 mRNA-1273 的年龄≥18 岁的个体，按年龄、性别和种族/族裔与随机选择的未接种个体 1:1 匹配，随访至 2021 年 9 月。结果为 SARS-CoV-2 感染、COVID-19 住院和住院死亡。使用 Cox 比例风险模型估计调整后的危险比（aHR），比较接种组和未接种组的结局。调整后的 VE（%）计算为（1-aHR）x100。还按年龄、性别、种族/族裔以及 Delta 期（2021 年 6 月至 9 月）估计 SARS-CoV-2 感染的 HR 和 VE。接种后 0-<2、2-<4、4-<6 和 6-<8 个月时，估计针对 SARS-CoV-2 感染和 COVID-19 住院的 VE。
结果
927004 名接受 2 剂 mRNA-1273 治疗的患者与 927004 名未接种患者相匹配。针对 SARS-CoV-2 感染的 VE（95%CI）为 82.8%（82.2-83.3%），针对 COVID-19 住院的 VE 为 96.1%（95.5-96.6%），针对 COVID-19 住院死亡的 VE 为 97.2%（94.8-98.4%）。SARS-CoV-2 感染的 VE 与年龄、性别和种族/族裔无差异，在 Delta 期为 86.5%（84.8-88.0%）。接种后 0-<2 个月的 SARS-CoV-2 感染 VE 为 88.0%，至 6-<8 个月时降至 75.5%。
结论
这些中期结果提供了持续的证据，证明 2 剂 mRNA-1273 可在接种后 8 个月内预防 SARS-CoV-2 感染，预防 COVID-19 住院和住院死亡，并可预防 Delta 期的 SARS-CoV-2 感染。
Zotero 插件